Preferred Biosimilar Products
Erythropoiesis-Stimulating-Agents (ESA) &
Granulocyte Colony-Stimulating Factors (C-GSFs)
Preferred Biosimilar Products
Effective June 1, 2019, Retacrit® (epoetin alfa-epbx) will be the preferred erythropoiesis-stimulating agent (ESA) on the CenCal Health Formulary. Epogen® and Procrit® will be removed from the CenCal Health formulary and will require a prior authorization indicating a trial/failure of the preferred ESA product.
Effective June 1, 2019, Zarxio® (filgrastim-sndz), Nivestym® (fligrastim-aafi), Fulphila® (pegfilgrastim-jmdb) and Udenyca® (pegfilgrastim-sbqv) will be the preferred Granulocyte Colony-Stimulating Factors (C-GSFs) on the CenCal Health Formulary. Neupogen® and Neulasta® will be removed from the CenCal Health formulary and will require a prior authorization indicating a trial/failure of the preferred C-GSF product.
Biosimilar Facts:
- Biosimilars are biologic medicines that are highly similar to their reference biologic, demonstrating no clinically meaningful differences in safety, purity, and potency comparted to that of the reference product.
- All Biosimilar Products have been approved by the FDA
- Biosimilars are not interchangeable with the reference products and will require a new prescription from the prescriber
Please contact CenCal Health Pharmacy Department with questions at (805) 562-1080
Opioid Updates 2019
Opioid and Benzodiazepine Concomitant Use Safety Edit
With the approval of CenCal Health's Pharmacy and Therapeutics Committee and in coordination with its Pharmacy Benefits Manager (MedImpact), CenCal Health continues to implement a multi-phase plan to deter over-utilization of opioids, and update utilization management measures.
Effective 9/1/2019, CenCal Health will implement an opioid and benzodiazepine concomitant use safety edit. The safety edit is a point of sale (POS) intervention that will identify and deny concurrent use of opioids and benzodiazepines when there is any overlap in the day supply. Interventions will work bi-directionally and stop claims when there is an opioid-benzodiazepine claim overlap or vice versa.
In order to override these rejections, the pharmacist may conduct a Drug Utilization Review (DUR) and submit the applicable override that outlines the specific actions taken by the pharmacist. The dispensing pharmacist can bypass the soft edit by using the following overrides:
| 4C (Hospice) |
1A (Filled As Is, False Positive)
|
| 4B (Palliative Care) |
1B (Filled As Is, Not Relevant) |
| 4D (Cancer) |
4A (Prescribed with Acknowledgements) |
| 1G (Prescriber Approval) |
3G (Drug Therapy Unchanged) |
Further details on the opioid and benzodiazepine concomitant use safety edit will be available in the August provider bulletin, and through the CenCal Health Pharmacy web-page.
If you have questions or need additional information, please contact the CenCal Health Pharmacy Department at (805) 562-1080.
2019 Formulary Updates